Medifast (MED) Stock Price, News & Analysis

Company Overview

Medifast, Inc. (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions. The company went public in 2001 and has since expanded its operations beyond the United States, serving customers in both the U.S. and Canada. Its offerings are distributed through a combination of e-commerce platforms and regional distribution centers, enabling efficient delivery of products to end users and reinforcing Medifast’s direct‐to‐consumer business model.

Under the leadership of President and Chief Executive Officer Daniel Chard, Medifast continues to invest in product innovation, digital tools and community building to strengthen customer engagement and retention. The company’s management team emphasizes evidence‐based program development and high standards of quality control, reflecting its commitment to clinical rigor and long‐term client success. With a focus on metabolic health and sustainable lifestyle transformation, Medifast aims to maintain its position as a leader in the weight‐management industry.

Key Stats

• Today's Range: $12.81 to $13.12
• 50-Day Range: $12.83 to $14.58
• 52-Week Range: $11.57 to $21.98
• Volume: 150,563 shs
• Average Volume: 146,574 shs
• Market Capitalization: $141.82 million
• P/E Ratio: 40.32
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Reduce

Medifast Stock Analysis - MarketRank™

Medifast scored higher than 76% of companies evaluated by MarketBeat, and ranked 65th out of 156 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Medifast has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Medifast has a consensus price target of $16.50, representing about 27.9% upside from its current price of $12.90.

Amount of Analyst Coverage

Medifast has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 200.00%

Earnings Growth

Earnings for Medifast are expected to grow by 200.00% in the coming year, from $0.51 to $1.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medifast is 40.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 225.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medifast is 40.32, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 17.76.

Price to Book Value per Share Ratio

Medifast has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.96% of the float of Medifast has been sold short.

Short Interest Ratio / Days to Cover

Medifast has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Medifast has recently decreased by 10.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Medifast does not currently pay a dividend.

Dividend Growth

Medifast does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Medifast is 2,062.50%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on EPS estimates, Medifast will have a dividend payout ratio of 431.37% in the coming year. This indicates that Medifast may not be able to sustain their current dividend.

Sustainability and ESG

• Score: 2.0 / 5
• Environmental Score: -4.00

Percentage of Shares Shorted

19.96% of the float of Medifast has been sold short.

Short Interest Ratio / Days to Cover

Medifast has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Medifast has recently decreased by 10.68%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

Medifast has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Consumer Staples companies.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medifast insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.90% of the stock of Medifast is held by insiders.

Percentage Held by Institutions

95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MED Stock Analysis - Frequently Asked Questions

How have MED shares performed this year?

Medifast's stock was trading at $17.62 at the beginning of 2025. Since then, MED shares have decreased by 26.8% and is now trading at $12.9030.

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) issued its quarterly earnings data on Monday, August, 4th. The specialty retailer reported $0.04 EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.26. The specialty retailer had revenue of $105.56 million for the quarter, compared to analysts' expectations of $96.10 million. Medifast had a trailing twelve-month return on equity of 2.00% and a net margin of 0.76%.
Read the conference call transcript.

Who are Medifast's major shareholders?

Medifast's top institutional shareholders include Exchange Traded Concepts LLC (0.17%) and CWM LLC (0.14%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist.
View institutional ownership trends.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 10/18/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Consumer Staples
• Industry: FOOD - MISC/DIVERSIFIED
• Sub-Industry: Personal Products
• Current Symbol: NYSE:MED
• CIK: 910329
• Web: www.medifast1.com
• Phone: (410) 581-8042
• Fax: 410-581-8070
• Employees: 870
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Medifast: $16.50
• High Price Target: $16.50
• Low Price Target: $16.50
• Potential Upside/Downside: +27.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.32
• Trailing P/E Ratio: 40.32
• Forward P/E Ratio: 25.30
• P/E Growth: N/A
• Net Income: $2.09 million
• Net Margins: 0.76%
• Pretax Margin: 1.30%
• Return on Equity: 2.00%
• Return on Assets: 1.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.47
• Quick Ratio: 3.82

Sales & Book Value

• Annual Sales: $480.45 million
• Price / Sales: 0.30
• Cash Flow: $2.95 per share
• Price / Cash Flow: 4.38
• Book Value: $19.21 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 10,991,000
• Free Float: 10,672,000
• Market Cap: $141.82 million
• Optionable: Optionable
• Beta: 0.85